Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The anthracyclines: when good things go bad.

Giorgio Minotti, Narine Sarvazyan

    Cardiovascular Toxicology
    |July 27, 2007
    PubMed
    Summary
    This summary is machine-generated.

    Anthracyclines remain vital cancer treatments despite their age. However, their significant cardiotoxicity, worsened by new drug combinations, necessitates strategies to mitigate heart damage.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Pharmacological strategies to prevent cancer therapy-related cardiovascular toxicity: the road to personalised cardioprotection.

    Heart (British Cardiac Society)·2026
    Same author

    Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

    Leukemia·2025
    Same author

    Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

    Leukemia·2025
    Same author

    Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind?

    European cardiology·2025
    Same author

    Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

    Leukemia·2025
    Same author

    Clinical Pharmacology: A new article type for The Journal of Pharmacology and Experimental Therapeutics.

    The Journal of pharmacology and experimental therapeutics·2025

    Area of Science:

    • Oncology
    • Cardiology
    • Pharmacology

    Background:

    • Anthracyclines are established chemotherapeutic agents with a long history in cancer treatment.
    • Despite their age, anthracyclines remain crucial for treating various hematological malignancies and solid tumors.

    Discussion:

    • The primary limitation of anthracyclines is their dose-dependent cardiotoxicity, a known risk since their introduction.
    • Emerging evidence indicates that novel combination therapies may exacerbate anthracycline-induced cardiotoxicity, increasing cardiac vulnerability.

    Key Insights:

    • Anthracyclines demonstrate enduring efficacy in oncology, challenging perceptions of their obsolescence.
    • Cardiotoxicity remains a critical challenge, particularly when anthracyclines are combined with newer therapeutic agents.

    Related Experiment Videos

    Outlook:

    • Further research is needed to develop strategies for reducing anthracycline cardiotoxicity.
    • Optimizing anthracycline use in combination regimens is essential for improving patient outcomes and safety.